One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363577PMC
http://dx.doi.org/10.1054/bjoc.2000.1425DOI Listing

Publication Analysis

Top Keywords

retinoic acid
12
13-cis retinoic
8
randomized trial
4
trial 13-cis
4
acid children
4
children advanced
4
advanced neuroblastoma
4
neuroblastoma high-dose
4
high-dose therapy
4
therapy seventy-five
4

Similar Publications

Growth-plate (GP) injures in limbs and other sites can impair GP function and cause deceleration of bone growth, leading to progressive bone lengthening imbalance, deformities and/or physical discomfort, decreased motion and pain. At present, surgical interventions are the only means available to correct these conditions by suppressing the GP activity in the unaffected limb and/or other bones in the ipsilateral region. Here, we aimed to develop a pharmacologic treatment of GP growth imbalance that involves local application of nanoparticles-based controlled release of a selective retinoic acid nuclear receptor gamma (RARγ) agonist drug.

View Article and Find Full Text PDF

Transcriptome analysis reveals molecular mechanism of Dosinia corrugata in response to acute heat stress.

Comp Biochem Physiol Part D Genomics Proteomics

January 2025

College of Fisheries and Life Science, Dalian Ocean University, Dalian 116023, China; Engineering and Technology Research Center of Shellfish Breeding in Liaoning Province, Dalian Ocean University, Dalian 116023, China. Electronic address:

This study seeks to explore the molecular regulatory mechanism within Dosinia corrugata in response to extreme high-temperature conditions, aiming to enhance the sustainable development of the D. corrugata aquaculture industry. To identify heat-responsive genes and elucidate adaptive mechanisms, we conducted transcriptional profiling of D.

View Article and Find Full Text PDF

Conversion of placental hemogenic endothelial cells to hematopoietic stem and progenitor cells.

Cell Discov

January 2025

Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.

Hematopoietic stem and progenitor cells (HSPCs) are critical for the treatment of blood diseases in clinic. However, the limited source of HSPCs severely hinders their clinical application. In the embryo, hematopoietic stem cells (HSCs) arise from hemogenic endothelial (HE) cells lining the major arteries in vivo.

View Article and Find Full Text PDF

IRF1-RIG-I signaling defects in the aged alveolar epithelial cells may contribute to decreased pulmonary antiviral immune responses.

Mech Ageing Dev

January 2025

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; School of Life Sciences, Henan University, Kaifeng, Henan Province, China; Henan Key Laboratory of Synthetic Biology and Biomanufacturing, Henan University, Kaifeng, Henan Province 475004, China. Electronic address:

Background: Alveolar epithelial cells (AECs) are the primary targets of many pathogens and play an important role in sensing viruses and regulating immunity. Yet, little is known about the antiviral responses in the aged AECs.

Methods: The responses of young or aged AECs after viral infection were analyzed using methods such as flow cytometry, quantitative real-time PCR, Western blot detection, and transwell chemotaxis assay.

View Article and Find Full Text PDF

The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden for hospitals and patients. We evaluated the bioavailability of a novel encapsulated oral ATO formulation in APL patients in first complete remission during standard-of-care consolidation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!